A practical reference on Cardarine: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Weak central coherence theory hypothesizes that a limited ability to see the big picture underlies the central disturbance in autism. One strength of this theory is predicting special talents and peaks in performance in autistic people. Another theory, enhanced perceptual functioning, focuses more on the superiority of locally oriented and perceptual operations in autistic individuals. Yet another theory, monotropism, posits that autism stems from a different cognitive style, tending to focus attention and processing resources intensely, to the exclusion of other stimuli. These theories map well from the underconnectivity theory of autism.
=== Isomers === 3-CMC is a chloromethcathinone, which has two other positional isomers, namely 2-CMC and 4-CMC. These differ in the position of the chlorine atom on the phenyl ring. As well as 3-CMC, these molecules are both known designer drugs. Since 3-CMC contains a chiral center, there are two enantiomers, namely (S)-3-CMC and (R)-3-CMC. The products are most likely on the market as a racemic mixture of the two enantiomers, since separation would result in very high costs.
== Goals of Pharmacometabolomics == Pharmacometabolomics is thought to provide information that complements that gained from other omics, namely genomics, transcriptomics, and proteomics. Looking at the characteristics of an individual down through these different levels of detail, there is an increasingly more accurate prediction of a person's ability to respond to a pharmaceutical compound. The genome, made up of 25 000 genes, can indicate possible errors in drug metabolism; the transcriptome, made up of 85,000 transcripts, can provide information about which genes important in metabolism are being actively transcribed; and the proteome, >10,000,000 members, depicts which proteins are active in the body to carry out these functions. Pharmacometabolomics complements the omics with direct measurement of the products of all of these reactions, but with perhaps a relatively smaller number of members: that was initially projected to be approximately 2200 metabolites, but could be a larger number when gut derived metabolites and xenobiotics are added to the list. Overall, the goal of pharmacometabolomics is to more closely predict or assess the response of an individual to a pharmaceutical compound, permitting continued treatment with the right drug or dosage depending on the variations in their metabolism and ability to respond to treatment. Pharmacometabolomic analyses, through the use of a metabolomics approach, can provide a comprehensive and detailed metabolic profile or "metabolic fingerprint" for an individual patient.
== Past predictions == In May 1998, George Kennan described the US Senate vote to expand NATO to include Poland, Hungary, and the Czech Republic as "the beginning of a new cold war", and predicted that "the Russians will gradually react quite adversely and it will affect their policies". In 2001, foreign policy and security experts James M. Lindsay and Ivo Daalder described counterterrorism as the "new Cold War". British journalist Edward Lucas wrote in February 2008 that a new cold war between Russia and the West had already begun.
Sources: en.wikipedia.org
"The fibrous variant of Hashimoto's thyroiditis" (1974, with Austin L. Vickery Jr.) "Thymoma in a 12-year-old boy" (1976, with Jane Chatten) "Urinary Ultrastructural Findings in Fabry Disease" (1977, with Patricia J. Lyons) "Examination of Sputum in Legionnaire's Disease" (1978) "Legionnaires' disease: structural characteristics of the organism" (1978, with Philip Nash) "Leydig cell tumors of the testis" (1979, with I. Damjanov and M. A. Jewett) "Ultrastructural Features of Respiratory Cilia in Cystic Fibrosis" (1980, with Douglas S. Holsclaw Jr.) "Postinflammatory pseudotumors of the lung: fibrous histiocytoma and related lesions" (1980, with E. E. Schwartz and G. A. Mandell) "Tolmetin: Association With Reversible Renal Failure and Acute Interstitial Nephritis" (1981, with Ralph Capaldo, Erich A. Everts, and John G. DiGregorio) "Pleomorphism of Legionella pneumophila" (1984, with Shahab Hashemi, Kristy R. Brown, William A. Habib, and Jay M. Hammel) "Cilia in the Human Kidney" (1984, with Joseph J. Morgan) Legionellosis (1985) "Microscopic Nephrocalcinosis in Cystic Fibrosis" (1988, with Leslie J. Krueger and Bonita L. Falkner) "A Self-Limited Febrile Illness Produced in Guinea Pigs Associated With Oral Administration of Legionella pneumophila" (1988, with Jay M. Hammel, Joseph P. Matus, Ronald Poropatich, and Julian Katz) "Diagnostic value of electron microscopy on paraffin-embedded cytologic material" (1993, with Nancy A. Young and Sonya Naryshkin)
Van Krevelen diagrams are graphical plots developed by Dirk Willem van Krevelen (chemist and professor of fuel technology at the TU Delft) and used to assess the origin and maturity of kerogen and petroleum. The diagram cross-plots the hydrogen:carbon atomic ratio as a function of the oxygen:carbon atomic ratio. Beginning around 2003, the diagrams are often used to visualize data from mass spectrometry analysis, used for mixtures other than kerogen and petroleum. For example, the diagrams have been used in one analysis of the components in Scotch whiskey, and are used in characterizing Dissolved organic carbon (DOC) in waters and soils
==== Dosage and safety margin ==== The data sheets for meloxicam products for cats also state that: "Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels."
10 September – As the newly discovered BA.2.86 COVID-19 variant (known unofficially as Pirola) continues to spread, Professor Rowland Kao, an infections expert from the University of Edinburgh, calls for lateral flow COVID tests to be made freely available again. 13 September – Alister Jack, the Secretary of State for Scotland, confirms the UK government will not block Scottish Government plans for a drug consumption room pilot scheme in Scotland. 19 September – The Scottish Government begins its legal challenge against Westminster over the UK government's decision to block the controversial Gender Recognition Reform (Scotland) Bill. 20 September – Elena Whitham, the Minister for Drugs and Alcohol Policy, announces plans to launch a consultation on raising the minimum price of alcohol in Scotland to 65p a unit. 21 September – Hunter Street Health Centre in the East End of Glasgow is earmarked as the site of the UK's first legal drugs consumption centre. 26 September – Data released by National Records of Scotland indicates life expectancy in Scotland has fallen for the third consecutive year, with the average age now 76.5 years for men and 80.7 years for women; the decrease from 2022 is three weeks for men and six weeks for women. 27 September – Glasgow's Integration Joint Board approves the UK's first official drugs consumption room for illegal drugs.
This micelle controlled technique provides for unique opportunities for solving complicated separation problems. Despite the poor efficiency of MLC, it has been successfully used in many applications. The use of MLC in the future appears to be extremely advantages in the areas of physiological fluids, pharmaceuticals, and even inorganic ions. The technique has proven to be superior over ion-pairing and ion-exchange for many applications. As new approaches are developed to combat the poor efficiency of MLC, its application is sure to spread and gain more acceptance.
Sources: en.wikipedia.org
By 1960, these measures and pressure from insurance companies led to the disappearance of the shoe-mounted fluoroscope, at least in the United States. In Switzerland, there were 1,500 shoe-mounted fluoroscopes in use, 850 were required to be inspected by the Swiss Electrotechnical Association by a decree of the Federal Department of Home Affairs on October 7, 1963. The last one was decommissioned in 1990. In Germany, the machines were not banned until 1976. The fluoroscopy machine emitted uncontrolled X-rays, which continuously exposed children, parents, and sales staff. The all-wood cabinet of the machine did not prevent the X-rays from passing through, resulting in particularly high cumulative radiation levels for the cashier when the pedoscope was placed near the cash register. It is clear that the machine was not designed with proper safety measures in place, leading to dangerous levels of radiation exposure. The well-established long-term effects of X-rays, including genetic damage and carcinogenicity, suggest that the use of pedoscopes worldwide over several decades may have contributed to health effects. However, it cannot be definitively proven that they were the sole cause. For example, a direct link has been discussed in the case of basal cell carcinoma of the foot. In 1950, a case was published in which a shoe model had to have a leg amputated as a result.
Physical properties of the drug (hydrophobicity, pKa, solubility) The drug formulation (immediate release, excipients used, manufacturing methods, modified release – delayed release, extended release, sustained release, etc.) Whether the formulation is administered in a fed or fasted state Gastric emptying rate Circadian differences Interactions with other drugs/foods: Interactions with other drugs (e.g., antacids, alcohol, nicotine) Interactions with other foods (e.g., grapefruit juice, pomello, cranberry juice, brassica vegetables) Transporters: Substrate of efflux transporters (e.g. P-glycoprotein) Health of the gastrointestinal tract Enzyme induction/inhibition by other drugs/foods: Enzyme induction (increased rate of metabolism), e.g., Phenytoin induces CYP1A2, CYP2C9, CYP2C19, and CYP3A4 Enzyme inhibition (decreased rate of metabolism), e.g., grapefruit juice inhibits CYP3A → higher nifedipine concentrations Individual variation in metabolic differences Age: In general, drugs are metabolized more slowly in fetal, neonatal, and geriatric populations Phenotypic differences, enterohepatic circulation, diet, gender Disease state E.g., hepatic insufficiency, poor renal function Each of these factors may vary from patient to patient (inter-individual variation), and indeed in the same patient over time (intra-individual variation). In clinical trials, inter-individual variation is a critical measurement used to assess the bioavailability differences from patient to patient in order to ensure predictable dosing.
It's impossible for us to accept such a plan." On 9 June 2022, the SAGO group, in development of its function of advisor to the WHO, published its first preliminary report. This report summarised existing findings and recommended that further studies be undertaken into possibly pathways of emergence.
=== Environmental and physical factors === Susceptibility to vitiligo appears to be affected by region, especially early in life (e.g. a lack of exposure to microbes weakening the immune system). Most cases seem to start before the age of 20. An event like a sunburn, exposure to toxins, stress or emotional distress can trigger and/or exacerbate the condition. Existing cases of vitiligo may also be aggravated by temperature changes (causing dryness or sweating), poor hydration, or unprotected sun exposure. Skin depigmentation can occur at the site of physical trauma, an example of the Koebner phenomenon; unlike in other skin diseases, this can be caused by daily activities, especially chronic friction on particular areas of the body. The phenomenon occurs in a third of patients with NSV but is rarely seen in SV. Vitiligo may be a multifactorial disease, with environmental factors triggering preexisting genetic susceptibilities.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.